Login
Subscribe
April 26, 2012
This is an urgent alert for patients with diabetes and others who are using Victoza (liraglutide).
More than 150,000 prescriptions per month are being filled for Americans for a relatively new diabetes drug, Victoza (liraglutide), that Public Citizen just asked the FDA to ban because it puts patients at higher risk of thyroid cancer, pancreatitis, serious allergic reactions and kidney failure that outweigh any documented clinical benefits.
Victoza...
April 26, 2012
This is an urgent alert for patients with diabetes and others who are using Victoza (liraglutide).
More than 150,000 prescriptions per month are being filled for Americans for a relatively new diabetes drug, Victoza (liraglutide), that Public Citizen just asked the FDA to ban because it puts patients at higher risk of thyroid cancer, pancreatitis, serious allergic reactions and kidney failure that outweigh any documented clinical benefits.
Victoza (liraglutide) was approved in January 2010, against the advice of two reviewing FDA pharmacologists and an FDA clinical safety reviewer. The primary physician reviewing the drug for the FDA said that she "does not recommend approval of liraglutide at this time. In the United States, there are already 11 classes of drugs approved for glycemic control in type 2 diabetes. The need for new therapies for type 2 diabetes is not so urgent that one must tolerate a significant degree of uncertainty regarding serious risk concerns."
If you are using Victoza (liraglutide), go to your doctor and ask what safer diabetes drug you could be switched to.
The full text of our petition to the FDA can be found at: www.citizen.org/hrg2020.
